Abstracts tagged "autoantibodies"

Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Paul Studenic¹, Farideh Alasti², Daniel Aletaha³, Josef S. Smolen¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
Abstract Number: 84 • 2017 ACR/ARHP Annual Meeting
Physiological Autoantibodies Against the Endthelin Receptor Type-a Are Critically Involved in the Homeostasis of Immune Cells
Otávio Cabral-Marques¹, Harald Heidecke², Frank Petersen³, Xinhua Yu⁴ and Gabriela Riemekasten⁵, ¹Department of Rheumatology, Vasculitis Center UKSH, University of Lübeck, Luebeck, Germany, ²CellTrend GmbH Luckenwalde, Luckenwalde, Germany, ³Research Centre Borstel, Borstel, Germany, ⁴Lung Centre Borstel, a Leibniz institute, Borstel, Germany, ⁵Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: G protein-coupled receptors (GPCRs) are a family of integral membrane proteins mediating cell trafficking and cellular homeostasis. In the last decades, several functional autoantibodies…
Abstract Number: 968 • 2017 ACR/ARHP Annual Meeting
Mononuclear Phagocytes Mediate Systemic Autoimmune Disease-Related Valvular Heart Disease Via Inflammatory Cytokine Production and Recruitment of Tissue-Reparative macrophages
Lee Meier¹, Jennifer L. Auger², Brianna J. Engelson³, Hannah Cowan³, Elise Breed⁴, Mayra Gonzalez-Torres⁵, Joshua Boyer⁶ and Bryce A. Binstadt⁷, ¹Peadiatrics, University of Minnesota, Minneapols, MN, ²Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ³Pediatrics, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota Medical School, Minneapolis, MN, ⁵University of Puerto Rico, Ponce, Puerto Rico, ⁶University of California, San Diego, San Diego, CA, ⁷remove this, remove this, remove this, MN
Background/Purpose:Cardiovascular comorbidity is significant in patients with systemic autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus . T cell receptor transgenic K/B.g7 mice develop…
Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Danielle Baldo¹, Alessandra Dellavance¹, Maria Lucia Ferraz² and Luis Eduardo C. Andrade^3,4, ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…
Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting
Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Tiezheng Yuan¹, Michelle Petri², Alan N. Baer³ and H. Benjamin Larman¹, ¹Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
Abstract Number: 404 • 2017 ACR/ARHP Annual Meeting
Gut Microbiota Modify Inflammatory Arthritis through Autoantibody Generation and Mucosal Cytokines Alteration
Widian Jubair¹, Sumitra Adhikari², Nirmal Banda² and Kristine Kuhn³, ¹Rheumatology, University of Colorado, Aurora, CO, ²Division of Rheumatology, UC Denver School of Medicine, Denver, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is thought to be influenced by a combination of genetic and environmental factors. Observations of microbial dysbiosis in…
Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Chaim Putterman¹, Armando Gabrielli², Alexandra Balbir-Gurman³, Pennina Safer⁴, Keren Jakobi-Brook⁴, Rachel Sorek⁴, Ilana Gluzman⁴, Steve Wallace⁵ and Irun R. Cohen^4,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, ³Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁴ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁵ImmunArray Inc., VA, USA, Richmond, VA, ⁶Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
Abstract Number: 2131 • 2017 ACR/ARHP Annual Meeting
Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
Rebecca De Lorenzo¹, Iago Pinal-Fernandez², Maria Casal-Dominguez², Wilson Huang², Jose Cesar Milisenda¹, Cassie Parks², Katherine Pak³, Cheilonda Johnson⁴, Eleni Tiniakou⁵, Jemima Albayda⁶, Julie J. Paik⁶, Sonye K. Danoff⁷, Lisa Christopher-Stine⁷, Andrea Corse⁸ and Andrew Mammen^3,9, ¹Muscle Disease Unit, NIAMS, NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Medicine/Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Neurology, Johns Hopkins University, Baltimore, MD, ⁹Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To describe the clinical and serologic features, as well as the disease course and response to therapy of anti-PM/Scl patients. Methods: All Johns Hopkins…
Abstract Number: 2974 • 2017 ACR/ARHP Annual Meeting
B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Scott Jenks¹, Joseph Marcus², Kevin Cashman¹ and Ignacio Sanz³, ¹Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ²San Antonio Uniformed Services Health Education Consortium, San Antonio, TX, ³Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: SLE is characterized by the dysregulation of humoral immunity including high levels of autoreactive IgG VH4.34 antibodies recognized by the rat anti-human idiotypic antibody…
Abstract Number: 562 • 2017 ACR/ARHP Annual Meeting
Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization
Syed M.S. Quadri¹, Biji T Kurien², Kristi A. Koelsch³ and R. Hal Scofield⁴, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjogren’s syndrome (SS) is a chronic autoimmune inflammatory disease characterized by impaired function of salivary and lacrimal glands leading to dry mouth and dry…
Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting
Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Petra Budde¹, Jennifer Marte², Hans-Dieter Zucht¹, Saurabh Bhandari¹, Manuel Tuschen¹, Peter Schulz-Knappe¹, James Gulley², Christopher Heery³, Ravi Madan² and Jeffrey Schlom², ¹Protagen AG, Dortmund, Germany, ²National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Bavarian Nordic, Inc., Morrisville, NC
Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…
Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…

« Previous Page
1
…
8
9
10
11
12
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].